191 related articles for article (PubMed ID: 20158215)
1. Bridged beta(3)-peptide inhibitors of p53-hDM2 complexation: correlation between affinity and cell permeability.
Bautista AD; Appelbaum JS; Craig CJ; Michel J; Schepartz A
J Am Chem Soc; 2010 Mar; 132(9):2904-6. PubMed ID: 20158215
[TBL] [Abstract][Full Text] [Related]
2. Thermodynamic and computational studies on the binding of p53-derived peptides and peptidomimetic inhibitors to HDM2.
Grässlin A; Amoreira C; Baldridge KK; Robinson JA
Chembiochem; 2009 May; 10(8):1360-8. PubMed ID: 19408261
[TBL] [Abstract][Full Text] [Related]
3. Miniature protein inhibitors of the p53-hDM2 interaction.
Kritzer JA; Zutshi R; Cheah M; Ran FA; Webman R; Wongjirad TM; Schepartz A
Chembiochem; 2006 Jan; 7(1):29-31. PubMed ID: 16397877
[No Abstract] [Full Text] [Related]
4. Beta-peptides with improved affinity for hDM2 and hDMX.
Harker EA; Daniels DS; Guarracino DA; Schepartz A
Bioorg Med Chem; 2009 Mar; 17(5):2038-46. PubMed ID: 19211253
[TBL] [Abstract][Full Text] [Related]
5. Helical beta-peptide inhibitors of the p53-hDM2 interaction.
Kritzer JA; Lear JD; Hodsdon ME; Schepartz A
J Am Chem Soc; 2004 Aug; 126(31):9468-9. PubMed ID: 15291512
[TBL] [Abstract][Full Text] [Related]
6. A Cyclized Helix-Loop-Helix Peptide as a Molecular Scaffold for the Design of Inhibitors of Intracellular Protein-Protein Interactions by Epitope and Arginine Grafting.
Fujiwara D; Kitada H; Oguri M; Nishihara T; Michigami M; Shiraishi K; Yuba E; Nakase I; Im H; Cho S; Joung JY; Kodama S; Kono K; Ham S; Fujii I
Angew Chem Int Ed Engl; 2016 Aug; 55(36):10612-5. PubMed ID: 27467415
[TBL] [Abstract][Full Text] [Related]
7. Discovery of α-helix-mimicking sulfono-γ-AApeptides as p53-MDM2 inhibitors.
Shi Y; Sang P; Cai J
Future Med Chem; 2021 Jun; 13(12):1021-1023. PubMed ID: 33906432
[No Abstract] [Full Text] [Related]
8. Cell-permeable beta-peptide inhibitors of p53/hDM2 complexation.
Harker EA; Schepartz A
Chembiochem; 2009 Apr; 10(6):990-3. PubMed ID: 19266537
[TBL] [Abstract][Full Text] [Related]
9. Conjugation of spermine enhances cellular uptake of the stapled peptide-based inhibitors of p53-Mdm2 interaction.
Muppidi A; Li X; Chen J; Lin Q
Bioorg Med Chem Lett; 2011 Dec; 21(24):7412-5. PubMed ID: 22047690
[TBL] [Abstract][Full Text] [Related]
10. Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction.
Cummings MD; Schubert C; Parks DJ; Calvo RR; LaFrance LV; Lattanze J; Milkiewicz KL; Lu T
Chem Biol Drug Des; 2006 Mar; 67(3):201-5. PubMed ID: 16611213
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
12. Effect of introducing aib in a designed helical inhibitor of hdm2-p53 interaction: A molecular dynamics study.
Chattopadhyay S; Ajani H; Basu G
Biopolymers; 2016 Jan; 106(1):51-61. PubMed ID: 26537425
[TBL] [Abstract][Full Text] [Related]
13. Overall Shape Constraint of Alternating α/β-Hybrid Peptides Containing Bicyclic β-Proline.
Wang S; Otani Y; Zhai L; Su A; Nara M; Kawahata M; Yamaguchi K; Sada A; Ohki R; Ohwada T
Org Lett; 2019 Oct; 21(19):7813-7817. PubMed ID: 31518151
[TBL] [Abstract][Full Text] [Related]
14. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
[TBL] [Abstract][Full Text] [Related]
15. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.
Parks DJ; LaFrance LV; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Schubert C; Koblish HK; Zhao S; Franks CF; Lattanze J; Carver TE; Cummings MD; Maguire D; Grasberger BL; Maroney AC; Lu T
Bioorg Med Chem Lett; 2006 Jun; 16(12):3310-4. PubMed ID: 16600594
[TBL] [Abstract][Full Text] [Related]
16. Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions.
Hara T; Durell SR; Myers MC; Appella DH
J Am Chem Soc; 2006 Feb; 128(6):1995-2004. PubMed ID: 16464101
[TBL] [Abstract][Full Text] [Related]
17. hDM2 protein-binding peptides screened from stapled α-helical peptide phage display libraries with different types of staple linkers.
Anananuchatkul T; Tsutsumi H; Miki T; Mihara H
Bioorg Med Chem Lett; 2020 Dec; 30(23):127605. PubMed ID: 33038548
[TBL] [Abstract][Full Text] [Related]
18. Probing Protein Surfaces: QSAR Analysis with Helix Mimetics.
Azzarito V; Rowell P; Barnard A; Edwards TA; Macdonald A; Warriner SL; Wilson AJ
Chembiochem; 2016 Apr; 17(8):768-73. PubMed ID: 26690307
[TBL] [Abstract][Full Text] [Related]
19. Design of a novel MDM2 binding peptide based on the p53 family.
Madhumalar A; Lee HJ; Brown CJ; Lane D; Verma C
Cell Cycle; 2009 Sep; 8(17):2828-36. PubMed ID: 19713735
[TBL] [Abstract][Full Text] [Related]
20. Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53-MDM2 interaction.
Li C; Zhan C; Zhao L; Chen X; Lu WY; Lu W
Bioorg Med Chem; 2013 Jul; 21(14):4045-50. PubMed ID: 23660015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
